Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Contact:Michael AlmstetterAm Klopferspitz 19aD-82152 MartinsriedPhone: +49 (0) 89 7801676-0Fax: +49 (0) 89 7801676-777E-Mail: info@origenis.deInternet: www.origenis.deorigenis GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Small Molecules, Molecular Modelling, Medicinal Chemistry,Combinatorial Chemistry, AutomationOrigenis is a leader in small molecule drug discovery with over 14 years ofexperience in the field. Origenis is a privately owned company based inMartinsried, Germany. Origenis runs its own patented Drug Discovery platformMOREsystem ® . The unique platform combines state-of-the-art drugdesign, patent analysis, chemical synthesis and biological characterizationperformed in an integrated manner on 20.000 square feet of integrated labspace. Origenis runs research alliances as well as active in-house programs.Origenis is currently focusing on anti-inflammatory and CNS drugs. Origenisis offering a variety of out-licensing opportunities.Orion Clinical Services GmbHCROContact:Dr. Jörg RenneckeElsenheimerstr. 61D-80667 MünchenPhone: +49 (0) 2241 97398-201Fax: +49 (0) 2241 97398-200E-Mail: Joerg.Rennecke@orioncro.comInternet: www.orioncro.comKeywords: Drug Development, Medical Writing, Monitoring, Clinical ResearchORION Clinical Services is a full-service clinical development organisationperforming all aspects of clinical trials internationally. The company is adynamic, proactive, multicultural CRO, offering a high quality, customisedand flexible service.ORION s European operations are managed from offices in the UnitedKindom, France and Germany, while North America is managed from theUSA, and Australasia from Australia. These central hubs are augmentedby regional staff – who are particularly important in providing coverage ofcentral and Eastern Europe.Founded in 1997, ORION Clinical Services has steadily built a reputation builton quality and reliability.Otsuka Novel Products GmbHPHARMA & CHEMICAL INDUSTRYContact:Dr. Katharina ThieleKeywords: Drug Development, Clinical Diagnostics, Antibiotics, InfectiousDiseasesErika-Mann-Str. 21D-80636 MünchenPhone: +49 (0) 89 2060205 20Fax: +49 (0) 89 2060205 55E-Mail: kthiele@otsuka.deInternet: www.otsuka.deOtsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as anOtsuka group company. With an international network of 145 subsidiariesand 39,000 employees in 23 countries, and regions across Europe, Asiapacific,America and the Middle East, Otsuka researches, develops, manufacturesand markets innovative and original products with a focus on pharmaceuticalproducts for the treatment of diseases. ONPG will initially focuson infectious diseases, working in collaboration with other group companiesto develop improved diagnostic tools and novel products for the treatmentof tuberculosis.96